State of New Jersey Common Pension Fund D Grows Holdings in Cardlytics, Inc. (NASDAQ:CDLX)

State of New Jersey Common Pension Fund D grew its holdings in Cardlytics, Inc. (NASDAQ:CDLXGet Rating) by 13.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 44,274 shares of the company’s stock after purchasing an additional 5,157 shares during the period. State of New Jersey Common Pension Fund D owned about 0.13% of Cardlytics worth $2,434,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. CAS Investment Partners LLC increased its stake in shares of Cardlytics by 0.7% during the fourth quarter. CAS Investment Partners LLC now owns 5,186,466 shares of the company’s stock valued at $342,774,000 after buying an additional 36,875 shares during the period. KPS Global Asset Management UK Ltd increased its stake in shares of Cardlytics by 5.9% during the fourth quarter. KPS Global Asset Management UK Ltd now owns 1,246,830 shares of the company’s stock valued at $82,403,000 after buying an additional 70,000 shares during the period. Jennison Associates LLC increased its stake in shares of Cardlytics by 194.7% during the fourth quarter. Jennison Associates LLC now owns 569,924 shares of the company’s stock valued at $37,666,000 after buying an additional 376,539 shares during the period. Geode Capital Management LLC increased its stake in shares of Cardlytics by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 569,883 shares of the company’s stock valued at $37,663,000 after buying an additional 24,467 shares during the period. Finally, Brightlight Capital Management LP increased its stake in shares of Cardlytics by 36.3% during the fourth quarter. Brightlight Capital Management LP now owns 546,131 shares of the company’s stock valued at $36,094,000 after buying an additional 145,586 shares during the period. Hedge funds and other institutional investors own 97.57% of the company’s stock.

Cardlytics Price Performance

Shares of NASDAQ CDLX opened at $15.07 on Wednesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.29 and a current ratio of 1.29. The company has a market cap of $514.19 million, a PE ratio of -6.73 and a beta of 2.10. The business has a 50-day simple moving average of $21.28 and a two-hundred day simple moving average of $40.76. Cardlytics, Inc. has a fifty-two week low of $11.95 and a fifty-two week high of $128.53.

Cardlytics (NASDAQ:CDLXGet Rating) last issued its quarterly earnings results on Monday, May 2nd. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($1.11) by $0.36. The business had revenue of $67.93 million during the quarter, compared to the consensus estimate of $65.84 million. Cardlytics had a negative return on equity of 13.81% and a negative net margin of 25.06%. During the same quarter last year, the company earned ($0.59) earnings per share. As a group, equities analysts expect that Cardlytics, Inc. will post -2.95 EPS for the current fiscal year.

Insiders Place Their Bets

In other Cardlytics news, CFO Andrew Christiansen sold 9,320 shares of the firm’s stock in a transaction dated Thursday, May 5th. The stock was sold at an average price of $34.38, for a total value of $320,421.60. Following the completion of the sale, the chief financial officer now owns 19,513 shares of the company’s stock, valued at $670,856.94. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CFO Andrew Christiansen sold 9,320 shares of Cardlytics stock in a transaction dated Thursday, May 5th. The stock was sold at an average price of $34.38, for a total transaction of $320,421.60. Following the completion of the sale, the chief financial officer now owns 19,513 shares of the company’s stock, valued at $670,856.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Lynne Marie Laube sold 17,973 shares of Cardlytics stock in a transaction dated Thursday, May 5th. The stock was sold at an average price of $33.60, for a total value of $603,892.80. Following the sale, the chief executive officer now directly owns 358,530 shares of the company’s stock, valued at approximately $12,046,608. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 36,275 shares of company stock valued at $1,202,223. 3.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Wells Fargo & Company lowered Cardlytics from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $72.00 to $15.00 in a research note on Thursday, July 14th. JPMorgan Chase & Co. cut their target price on Cardlytics from $47.00 to $35.00 and set a “neutral” rating on the stock in a research note on Wednesday, June 29th. Bank of America lowered Cardlytics from a “neutral” rating to an “underperform” rating and set a $14.00 target price on the stock. in a research note on Tuesday, July 12th. Craig Hallum lowered Cardlytics from a “buy” rating to a “hold” rating and cut their target price for the company from $50.00 to $20.00 in a research note on Tuesday, July 12th. Finally, Needham & Company LLC cut their target price on Cardlytics from $60.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday, July 13th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Cardlytics currently has a consensus rating of “Hold” and a consensus target price of $21.60.

About Cardlytics

(Get Rating)

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Further Reading

Want to see what other hedge funds are holding CDLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardlytics, Inc. (NASDAQ:CDLXGet Rating).

Institutional Ownership by Quarter for Cardlytics (NASDAQ:CDLX)

Want More Great Investing Ideas?

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.